Pemvidutide Dosing Guide: Schedule, Titration & What to Expect Each Week

Introduction

Pemvidutide is dosed once weekly by subcutaneous injection, and the titration plan tested in phase 2 trials uses monthly step-ups from 1.2 mg to 1.8 mg to 2.4 mg. The drug isn’t FDA-approved as of 2026, so there’s no official prescribing information yet, and the dosing reference points come from the MOMENTUM obesity trial and the IMPACT MASH trial.

This guide walks through the dosing schedule used in trials, why titration matters, what each week typically looks like during ramp-up, and how pemvidutide dosing might compare to semaglutide and tirzepatide once it reaches market.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the Standard Pemvidutide Dosing Schedule?

The pemvidutide dosing schedule used in the MOMENTUM phase 2 trial starts at 1.2 mg weekly for four weeks, increases to 1.8 mg weekly for four weeks, then either stays at 1.8 mg or steps up to 2.4 mg weekly as maintenance. The injection goes into subcutaneous fat in the abdomen, thigh, or upper arm.

Quick Answer: Pemvidutide is given once weekly subcutaneously

That titration plan mirrors how semaglutide and tirzepatide step patients up. The slow ramp gives the gut time to adapt to GLP-1 receptor activation, which lowers the rate of severe nausea and vomiting that would otherwise occur if patients started at the full dose.

Final approved dosing will depend on phase 3 trial design. Altimmune has signaled they’ll likely keep the same titration schedule but possibly extend the time at each dose if tolerance is the bottleneck.

Why Does Pemvidutide Need Titration at All?

Titration matters because GLP-1 receptor activation slows gastric emptying and triggers central nausea pathways. Patients who start at the full dose get severe GI side effects roughly 2 to 3x more often than patients who titrate. The receptor adapts (technically, downstream signaling desensitizes for the symptom pathways but not the appetite pathways), and four weeks at each dose is usually long enough.

Glucagon receptor activation adds a second reason to ramp slowly. The metabolic effects (increased heart rate, modest LDL increases, small fasting-glucose changes) build over time. Starting high would amplify those signals and might push some patients into safety stoppages.

In MOMENTUM, trial dropout for GI events was about 10 to 12% at 2.4 mg with titration, similar to semaglutide’s STEP 1 dropout rate (Wilding et al. 2021 NEJM).

What Does Week 1 on Pemvidutide Feel Like?

Most patients in MOMENTUM reported mild nausea within 24 to 48 hours of the first dose, sometimes peaking at days 2 to 4 and easing by day 5 or 6. Appetite suppression sets in quickly, often within the first three days. Food cravings drop and meal sizes shrink.

Some patients felt almost nothing the first week. That’s normal at the 1.2 mg starting dose, especially for patients who naturally tolerate GLP-1 effects well. Weight loss in week 1 is mostly water and gut content changes, not fat loss.

GI symptoms to watch for in week 1: mild nausea, decreased appetite, possibly mild constipation or loose stools, and occasionally fatigue or brain fog. Severe vomiting or sustained pain isn’t normal and needs medical attention.

What Changes During Weeks 2 Through 4?

Weeks 2 through 4 are when appetite suppression becomes the dominant felt effect. Patients report feeling full faster, going longer between hunger cues, and losing interest in foods they used to crave (especially high-fat or alcoholic items). Mean weight loss by week 4 in MOMENTUM was roughly 2 to 3% from baseline.

Side effects typically peak in week 2 then ease by week 4. The body adapts to receptor activation, and the dose escalation to 1.8 mg at week 5 starts the cycle over again, but usually with milder symptoms because the gut has already adjusted partway.

Hydration and electrolytes matter here. Reduced food and fluid intake plus possible GI losses can dehydrate patients fast. Most trial protocols specify monitoring fluid intake closely during week 2 onward.

What Happens at the 1.8 Mg Dose STEP?

At week 5, dose increases to 1.8 mg weekly. Most patients see a return of mild nausea or appetite changes for a few days after the first higher injection, then re-adapt. Weight loss curves accelerate slightly because the higher dose drives more sustained appetite suppression.

By week 8, mean weight loss in MOMENTUM was around 5 to 6%, with most of that being adipose tissue, some glycogen and water, and a small lean mass component. Patients who plateau or experience intolerable side effects at this dose can stay on 1.8 mg as a maintenance dose rather than escalating to 2.4 mg.

The 1.8 mg dose produced 11.2% weight loss at 48 weeks in MOMENTUM, which is clinically meaningful and may be the right maintenance dose for many patients depending on how phase 3 plays out.

What Happens at the 2.4 Mg Maintenance Dose?

The 2.4 mg dose is the highest tested in MOMENTUM and produced 15.6% weight loss at 48 weeks. After the step-up at week 9, side effects re-emerge briefly then settle by week 11 or 12 for most patients. Long-term tolerability looked acceptable in the trial.

Weight loss curves had not plateaued at week 48, which suggests there’s more weight to lose with longer treatment. A planned phase 3 obesity trial would likely run 72 weeks (matching SURMOUNT-1 and STEP 1 designs) and could push mean weight loss higher.

Heart rate and blood pressure should be monitored at this dose. Mean HR rose about 5 bpm at 2.4 mg in MOMENTUM. That’s not dangerous for most patients but matters for anyone with arrhythmia history or significant cardiovascular disease.

Can Pemvidutide Doses Be Split or Adjusted?

Doses are given as a single weekly injection. Splitting into smaller doses across the week isn’t part of any trial protocol and isn’t recommended because plasma levels would dip below therapeutic thresholds. The drug is designed around the weekly schedule made possible by the six-day half-life.

Dose adjustments downward (going from 2.4 back to 1.8, or 1.8 back to 1.2) are reasonable if side effects don’t resolve. That’s similar to how semaglutide and tirzepatide dosing flexes in clinical practice. Re-escalation can happen later if symptoms settle.

A missed dose can be taken up to 48 hours late without significant impact. After 48 hours, skip that week and resume the regular schedule with the next dose. Two missed doses in a row means re-titration from a lower dose.

How Does Pemvidutide Dosing Compare to Semaglutide?

Semaglutide for obesity (Wegovy®) titrates monthly from 0.25 mg to 2.4 mg over 16 weeks: 0.25, 0.5, 1.0, 1.7, 2.4. Pemvidutide tested a simpler 1.2 to 1.8 to 2.4 mg schedule over 8 weeks in MOMENTUM, so the ramp is shorter.

The mg doses aren’t directly comparable. Pemvidutide is a different peptide with different potency at the GLP-1 receptor plus added glucagon activity. The 2.4 mg dose doesn’t mean the same thing as semaglutide 2.4 mg.

Phase 3 trial design may extend the titration period for pemvidutide if intolerance signals show up in larger populations. That’s standard for late-stage development.

How Does Pemvidutide Dosing Compare to Tirzepatide?

Tirzepatide for obesity (Zepbound®) titrates monthly from 2.5 mg to 15 mg over 20 weeks. Maintenance options are 5, 10, or 15 mg. Pemvidutide has fewer dose levels to choose from in trial data so far.

In terms of effect, the 2.4 mg pemvidutide dose at 48 weeks (15.6%) is comparable to tirzepatide 5 mg territory in SURMOUNT-1 (which showed 15.0% at 72 weeks for 5 mg, Jastreboff et al. 2022 NEJM). Higher pemvidutide doses haven’t been tested.

What If I Want to Start Pemvidutide Now?

Pemvidutide isn’t available outside clinical trials. The only legitimate access path is enrolling in an Altimmune-sponsored phase 2 or phase 3 study through clinicaltrials.gov. Compounded pemvidutide is not legal because the drug isn’t FDA-approved.

Patients looking for similar mechanism right now can talk to a TrimRx clinician about whether semaglutide or tirzepatide fits their goals. The TrimRx free assessment quiz screens for relevant medical history, weight loss goals, and lifestyle factors that affect which compound makes sense.

When pemvidutide does reach market (likely 2027 to 2028 at earliest), TrimRx will evaluate carrying it once approved and prescribed under standard medical oversight.

Key Takeaway: Top dose tested in MOMENTUM (48-week phase 2) was 2.4 mg weekly

What Injection Technique Do Trials Use?

Subcutaneous injection into the abdomen (avoiding 2 inches around the navel), the front or outside of the thigh, or the back of the upper arm. Rotating sites week to week helps avoid lipohypertrophy or skin reactions.

The injection itself uses a 27 to 30 gauge needle, similar to semaglutide. Most patients describe the injection as quick and minimally painful, with mild stinging that resolves within seconds.

Pemvidutide is supplied as a solution. Bring it to room temperature for 15 to 30 minutes before injecting (out of the refrigerator) so the cold liquid doesn’t sting more than necessary.

What If Side Effects Don’t Improve with Titration?

If GI side effects persist past 6 to 8 weeks at a given dose, options include extending time at that dose before stepping up, dropping back to a lower dose, or stopping if symptoms are intolerable. Severe persistent nausea, vomiting, or abdominal pain warrants a clinician evaluation.

About 10 to 12% of patients in MOMENTUM stopped early due to GI events, which is similar to other GLP-1 drugs at high doses. The other 88 to 90% tolerated the full titration to 2.4 mg.

Antiemetics can help with nausea in the first few weeks but aren’t a long-term solution. Hydration, smaller meals, avoiding fatty or fried foods, and slow ramp-up are the standard mitigations.

How Does Pemvidutide’s Half-life Affect Dose Timing Flexibility?

The six-day half-life gives flexibility. Patients who normally inject on Sunday but find themselves traveling can usually shift by 1 to 2 days without significant problems, especially after reaching steady state at week 4 to 5.

Larger shifts (3 to 4 days late) reduce plasma levels but usually don’t cause complete loss of effect. Skipping an entire week drops levels meaningfully but residual drug stays above receptor activation threshold for several more days.

Consistency still matters. Regular weekly dosing produces predictable side effect patterns and steady weight loss curves. Repeated timing shifts can make side effect management harder.

What Does the First 30 Days Look Like in Detail?

Day 1: First injection at 1.2 mg. Mild nausea typically within 1 to 2 days. Appetite suppression begins.

Days 3 to 5: Nausea peaks. Appetite clearly reduced. Some mild fatigue possible.

Days 6 to 7: Symptoms easing. Weight loss minimal at this point (mostly water).

Week 2: Second injection. Symptoms milder than week 1. Appetite suppression strengthens.

Week 3: Third injection. Body adapting. Weight loss visible.

Week 4: Fourth and final injection at 1.2 mg. Cumulative weight loss 2 to 3%. Side effects substantially eased.

What Should Patients Do to Prepare for First Injection?

Practical preparation:

Confirm refrigerated storage. Pull product out 15 to 30 minutes before injecting. Clean injection site with alcohol swab. Choose a different site each week (rotate abdomen, thigh, upper arm). Have ginger chews or similar nausea aids on hand. Plan light meals for the day of injection, avoiding fatty or heavy foods.

Hydration matters. Aim for 64 to 80 oz daily starting a few days before first injection.

What If I Feel Nothing in the First Week?

A small minority of patients have minimal early response. Don’t increase the dose; continue the standard titration. Effects typically build over weeks 2 to 4 even if week 1 feels uneventful.

If 8 to 12 weeks at the 2.4 mg dose produces no weight loss and minimal appetite change, you’re probably a low responder. Talk to a clinician about options including extended time at the current dose, switching to a different GLP-1 drug, or considering non-GLP-1 approaches.

How Do Trial Participants Manage Dosing Logistics?

Trial participants receive pre-filled syringes at study visits and inject themselves at home weekly. Trial coordinators provide detailed instructions, support phone numbers, and follow-up scheduling.

Compliance with dosing schedule is part of trial protocol. Missed doses or significant deviations are reported to the trial team for guidance.

What About Transitioning to a Maintenance Routine?

Once at the 2.4 mg maintenance dose (week 9 onward), most patients establish a stable routine: same day of week, same time of day, same general injection approach. The drug becomes a background part of weekly life.

For long-term therapy (which is likely the eventual norm for obesity treatment with any GLP-1 drug), this routine becomes the default. Patients can travel, shift schedules slightly, and accommodate life events without significant disruption.

Bottom line: No FDA-approved dose schedule yet; phase 3 design will set the final approved regimen

FAQ

Can I Start Pemvidutide at the 2.4 Mg Dose?

No. Trials titrate from 1.2 mg to limit GI side effects. Starting at the full dose would likely cause severe nausea and vomiting in a large fraction of patients and could trigger early discontinuation.

How Long Until I See Weight Loss Results?

Most patients see 2 to 3% weight loss by week 4 and 5 to 6% by week 8 in trial data. Larger losses build through months 3 to 12 as appetite stays suppressed and adipose tissue mobilization continues.

Is There an Oral Pemvidutide Pill?

No. Pemvidutide is a peptide that would be destroyed in the stomach. Only subcutaneous injection is in development.

Can I Take Pemvidutide with Another GLP-1 Drug?

No. Combining GLP-1 agonists isn’t safe or evidence-based. Switch from one to another with a washout period rather than overlapping.

What Time of Day Should I Inject?

Any time of day works because of the long half-life. Most patients pick the same day each week for consistency. Many prefer evening injections so the peak nausea hits during sleep.

Will I Gain Weight Back If I Stop Pemvidutide?

The STEP 1 extension trial (Wilding 2022 Diabetes Obesity Metab) showed roughly two-thirds of semaglutide weight loss returns within a year of stopping. Pemvidutide is likely similar because the underlying biology is the same.

Can Pemvidutide Be Split Into Smaller Injections Through the Week?

No. The peptide is designed for once-weekly dosing based on its six-day half-life. Splitting wouldn’t maintain steady plasma levels.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.